Twenty five patients with Raynaud's phenomenon due to systemic sclerosis were infused with prostacyctin (PGI^). In 88",, of the patients there was objective improvement, monitored by thermography or radiometry.The pathogenesis of Raynaud's phenomenon is obscure. Therapy directed at over-activity of the sympathetic system produces only limited or short-lived improvement.Prostaglandins I2 and E, are potent vasodilators and inhibitors of platelet aggregation atid might be expected to produce improvement in peripheral blood fiow. The results of recent studies (Carlson & Eriksson, 1973;Carlson & Olsson, 1976;Szczeklik et al., 1979) suggest that these drugs may help in the management of peripheral vascular disease and ischaemic ulceration.In a previous controlled study of prostaglandin E, in patients with Raynaud's phenomenon and systemic sclerosis, we showed that the drug had a significantly better effect than placebo (Martin et al., I98ia,b).The efficacy of intravenous infusions of prostacyclin (PGI3), a potent vasodilator and more potent inhibitor of platelet aggregation, has now been assessed.
PATIENTS AND METHODSThe investigation was performed during the winter months, 1979-1980. Twenty-five patients (twenty-four female, one male) with symptomatic Raynaud's phenomenon and systemic sclerosis were treated with intravenous infusions of prostacyclin.The mean age of the patients was 51 years (range 24-73 years). The mean duration of the Raynaud's phenomenon was I2 years (range 9 months-30 years) and that of other clinical evidence of systemic sclerosis 6 years (range 4 months-i6 years). ooo7-0963/82/oioo-oo8i$02.oo ((J) 1982 British Association of Dermatologists 81